Cargando…
Maraba virus-vectored cancer vaccines represent a safe and novel therapeutic option for cats
Direct killing of malignant cells combined with induction of tumour-specific immune responses makes oncolytic vaccines attractive for cancer therapy. We previously developed a heterologous cancer immunization strategy that utilized a replication-defective adenovirus-vectored primary vaccine encoding...
Autores principales: | Hummel, Jeff, Bienzle, Dorothee, Morrison, Annette, Cieplak, Michelle, Stephenson, Kyle, DeLay, Josepha, Woods, J. Paul, Lichty, Brian D., Bridle, Byram W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5691073/ https://www.ncbi.nlm.nih.gov/pubmed/29146945 http://dx.doi.org/10.1038/s41598-017-15992-4 |
Ejemplares similares
-
Development and applications of oncolytic Maraba virus vaccines
por: Pol, Jonathan G, et al.
Publicado: (2018) -
Characterization of Kidney Injury Molecule‐1 in Cats
por: Bland, S.K., et al.
Publicado: (2014) -
Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer
por: McGray, A. J. Robert, et al.
Publicado: (2019) -
Characterizing Cellular Responses During Oncolytic Maraba Virus Infection
por: Hassanzadeh, Golnoush, et al.
Publicado: (2019) -
Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials
por: Pol, Jonathan G., et al.
Publicado: (2018)